UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2008
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER INFORMATION
On June 3, 2008, Integra LifeSciences Holdings Corporation issued a press
release announcing that it has scheduled a conference call for 9:00 AM ET on
Thursday, June 5, 2008, to discuss its financial results for the first quarter
ended March 31, 2008 and to update forward-looking financial guidance.
Access to the live call is available by dialing 913-312-1487 or through a
webcast via a link provided on the Investor Relations homepage of Integra's
website at www.Integra-LS.com. Access to a replay is available through June 19,
2008 by dialing 719-457-0820 (PIN 7222524) or through the webcast.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
- ---------- -----------
99.1 Press Release, dated June 3, 2008, issued by Integra
LifeSciences Holdings Corporation.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: June 4, 2008 By: /s/ Stuart M. Essig
-------------------------------------
Stuart M. Essig
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
- ---------- -----------
99.1 Press Release, dated June 3, 2008, issued by Integra
LifeSciences Holdings Corporation.
News Release
Contact:
Integra LifeSciences Holdings Corporation
John B. Henneman III Karen Mroz-Bremner
Executive Vice President, Senior Manager, Corporate Development
Finance and Administration, and and Investor Relations
Chief Financial Officer (609) 936-6929
(609) 936-2481 karen.mroz-bremner@Integra-LS.com
jhenneman@Integra-LS.com
Integra LifeSciences to Host First Quarter 2008 Financial Results
Conference Call on June 5, 2008
Plainsboro, New Jersey, June 3, 2008-- Integra LifeSciences Holdings Corporation
(NASDAQ:IART) has scheduled a conference call for 9:00 AM ET on Thursday, June
5, 2008 to discuss financial results for the first quarter ended March 31, 2008
and to update forward-looking financial guidance. Financial results for the
first quarter 2008 will be announced via a news release issued prior to the
call.
The conference call will be hosted by Stuart Essig, President and Chief
Executive Officer of Integra, and will be open to all listeners. Additional
forward-looking information may be discussed in a question and answer session
following the call.
Access to the live call is available by dialing 913-312-1487 or through a
webcast via a link provided on the Investor Relations homepage of Integra's
website at www.Integra-LS.com. Access to a replay is available through
June 19, 2008 by dialing 719-457-0820 (PIN 7222524) or through the webcast.
Integra LifeSciences Holdings Corporation, a world leader in regenerative
medicine, is dedicated to improving the quality of life for patients through the
development, manufacturing, and marketing of cost-effective surgical implants
and medical instruments. Our products are used primarily in neurosurgery,
extremity reconstruction, orthopedics and general surgery to treat millions of
patients every year. Integra's headquarters are in Plainsboro, New Jersey, and
we have research and manufacturing facilities throughout the world. Please visit
our website at (http://www.Integra-LS.com).
IART-G
Source: Integra LifeSciences Holdings Corporation